Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLARIII: Sintilimab + Neoadjuvant Chemoradiotherapy in Rectal Cancer
NCT07040098Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in rectal cancer (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Complete Response Rate. Started Jun 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07040098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040098.